Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
McKinsey
Boehringer Ingelheim
Medtronic
McKesson

Last Updated: March 24, 2023

Details for Patent: 7,919,118


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Summary for Patent: 7,919,118
Title:Spacer moiety for poly (ethylene glycol) modified peptide based compounds
Abstract: The present invention relates to a compound comprising a peptide moiety, a spacer moiety and a water-soluble polymer moiety such as a poly(ethylene glycol) moiety. The spacer moiety is between the peptide moiety and the water-soluble polymer moiety. The spacer moiety has the structure: --NH--(CH.sub.2).sub..alpha.--[O--(CH.sub.2).sub..beta.].sub..gamma.--O.s- ub..delta.--(CH.sub.2).sub..epsilon.--Y-- wherein .alpha., .beta., .gamma., .delta., and .epsilon. are each integers whose values are independently selected.
Inventor(s): Holmes; Christopher P. (Saratoga, CA), Yin; Qun (Palo Alto, CA), Tumelty; David (Sunnyvale, CA)
Assignee: Affymax, Inc. (
Application Number:10/555,860
Patent Claim Types:
see list of patent claims
Compound; Composition;

Drugs Protected by US Patent 7,919,118

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Takeda Pharms Usa OMONTYS peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-007 Mar 27, 2012 DISCN No No See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Takeda Pharms Usa OMONTYS peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-008 Mar 27, 2012 DISCN No No See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Takeda Pharms Usa OMONTYS PRESERVATIVE FREE peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-001 Mar 27, 2012 DISCN No No See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Takeda Pharms Usa OMONTYS PRESERVATIVE FREE peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-002 Mar 27, 2012 DISCN No No See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Takeda Pharms Usa OMONTYS PRESERVATIVE FREE peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-003 Mar 27, 2012 DISCN No No See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Takeda Pharms Usa OMONTYS PRESERVATIVE FREE peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-004 Mar 27, 2012 DISCN No No See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Takeda Pharms Usa OMONTYS PRESERVATIVE FREE peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-005 Mar 27, 2012 DISCN No No See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,919,118

PCT Information
PCT FiledMay 12, 2004PCT Application Number:PCT/US2004/014887
PCT Publication Date:November 25, 2004PCT Publication Number: WO2004/100997

International Family Members for US Patent 7,919,118

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2004238364 See Plans and Pricing
Brazil PI0411166 See Plans and Pricing
Canada 2525399 See Plans and Pricing
China 1849141 See Plans and Pricing
Eurasian Patent Organization 010015 See Plans and Pricing
Eurasian Patent Organization 200501800 See Plans and Pricing
European Patent Office 1628686 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKinsey
Johnson and Johnson
Medtronic
Colorcon
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.